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Abstract: Panic disorder (PD) is a common, persistent and disabling mental disorder. It is often 
associated with agoraphobia. The present article reviews the current status of pharmacotherapy 
for PD with or without agoraphobia as well as the current status of treatments combing pharma-
cotherapy with cognitive behavior therapy (CBT). The review has been written with a focus on 
randomized controlled trials, meta-analyses, and reviews that have been published over the past 
few years. Effective pharmacological treatments include tricyclic antidepressants, monoamine 
oxidase inhibitors, selective serotonin reuptake inhibitors, serotonin norepinephrine reuptake 
inhibitors, and various benzodiazepines. Treatment results obtained with CBT compare well with 
pharmacotherapy, with evidence that CBT is at least as effective as pharmacotherapy. Combining 
pharmacotherapy with CBT has been found to be superior to antidepressant pharmacotherapy or 
CBT alone, but only in the acute-phase treatment. Long term studies on treatments combining 
pharmacotherapy and CBT for PD with or without agoraphobia have found little beneﬁ  t, how-
ever, for combination therapies versus monotherapies. New investigations explore the potential 
additional value of sequential versus concomitant treatments, of cognitive enhancers and virtual 
reality exposure therapy, and of education, self management and Internet-based interventions.
Keywords: Panic disorder, agoraphobia, pharmacotherapy, cognitive-behavioral therapy, 
combination treatments.
Clinical presentation
Panic disorder (PD) is a common, persistent and disabling mental disorder. The efﬁ  cacy 
of various psychotropic medications (mainly antidepressants and benzodiazepines) as 
well as the efﬁ  cacy of cognitive behavior therapy (CBT) for treating the disorder has 
been established in numerous randomized controlled trials.
According to the Diagnostic and Statistical Manual of Mental Disorders, Fourth 
Edition, Text Revision (DSM-IV-TR) (American Psychiatric Association 2000), the 
essential feature of PD is the presence of recurrent, unexpected panic attacks, followed 
by at least 1 month of persistent concern about having another panic attack, worry 
about the possible implications or consequences of the panic attacks, or a signiﬁ  cant 
behavioral change related to the attacks. The panic attacks are not due to the direct 
physiological effects of a substance or a general medical condition, and are not better 
accounted for by another mental disorder.
In DSM-IV-TR, a panic attack is deﬁ  ned as a discrete period of intense fear or 
discomfort accompanied by at least 4 of 13 somatic or cognitive symptoms. The attack 
has a sudden onset and builds to a peak rapidly (usually in 10 minutes or less) and is 
often accompanied by a sense of imminent danger or impending doom and an urge to 
escape. The 13 somatic or cognitive symptoms are (1) palpitations, pounding heart, 
or accelerated heart rate; (2) sweating; (3) trembling or shaking; (4) sensations or 
shortness of breath or smothering; (5) feelings of choking; (6) chest pain or discomfort; 
(7) nausea or abdominal distress; (8) feeling dizzy, unsteady, light-headed, or faint; 
(9) derealization (feelings of unreality) or depersonalization (being detached from 
oneself); (10) fear of losing control or going crazy; (11) fear of dying; (12) paresthesias Neuropsychiatric Disease and Treatment 2008:4(4) 780
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(numbness or tingling sensations); and (13) chills or hot 
ﬂ  ushes. Panic attacks that meet all other criteria but that have 
fewer than 4 somatic or cognitive symptoms are referred to 
as limited-symptom attacks.
According to DSM-IV-TR, the essential feature of ago-
raphobia is anxiety about being in places or situations from 
which escape might be difﬁ  cult (or embarrassing) or in which 
help may not be available in the event of having a panic 
attack or panic-like symptoms. The anxiety typically leads 
to a pervasive avoidance of a variety of situations that may 
include being alone outside the home or being home alone; 
being in a crowd of people; travelling in a automobile, bus, 
or airplane; or being on a bridge or in an elevator. Some indi-
viduals are able to expose themselves to the feared situations 
but endure these experiences with considerable dread. Others 
require the presence of a companion to confront the feared 
situation. Individuals’ avoidance of situations may impair 
their ability to travel to work or to carry out homemaking 
responsibilities. According to DSM-IV-TR, agoraphobia may 
develop at any point in the course of PD, but onset is usually 
within the ﬁ  rst year of occurrence of panic attacks.
There are 3 characteristic types of panic attacks, with 
different relationships between the attack and the presence 
or absence of situational triggers: unexpected (uncued) 
panic attacks, situationally bound (cued) panic attacks, and 
situationally predisposed panic attacks. Panic attacks can 
occur in a variety of anxiety disorders, eg, PD, social phobia, 
speciﬁ  c phobia, acute stress disorder, and post-traumatic 
stress disorder. In DSM-IV-TR, the occurrence of at least 
2 unexpected panic attacks is required for a diagnosis of PD 
with or without agoraphobia.
Depending on whether criteria are also met for agora-
phobia, PD with agoraphobia or PD without agoraphobia 
is diagnosed. PD without agoraphobia is characterized by 
recurrent unexpected panic attacks and by the absence of 
agoraphobia. PD with agoraphobia is characterized by both 
recurrent unexpected panic attacks and agoraphobia.
Prevalence
PD with or without agoraphobia is a highly prevalent psychiat-
ric disorder that affects up to 5% of the population at some point 
in life. As shown by the results of the National Comorbidity 
Survey Replication (Kessler et al 2006), life-time prevalence for 
PD with agoraphobia is 1.1 and 3.7 for PD without agoraphobia. 
PD with agoraphobia is diagnosed 3 times as often, and PD 
without agoraphobia twice as often in women as in men. PD is 
often disabling, especially when complicated by agoraphobia. 
The disorder may persist for years and be associated with a 
considerable impairment in functioning and with a substantial 
reduction in quality of life. PD with or without agoraphobia 
is associated with increased use of health care, high rates of 
absenteeism, and reduced workplace productivity.
Pharmacotherapy
Medications with proven efﬁ  cacy in PD include various    
antidepressants (TCAs), monoamine oxidase (MOA) 
inhibitors, selective serotonin reuptake inhibitors (SSRIs), 
serotonin norepinephrine reuptake inhibitors (SNRIs), and 
benzodiazepines.
Tricyclic antidepressants
The efﬁ  cacy of the tricyclic antidepressant imipramine for 
treating PD was ﬁ  rst shown by Donald Klein (1964). After 
Klein’s ﬁ  ndings, other tricyclic antidepressants were found 
to be effective for treating the disorder.
The current use of tricyclic antidepressants for treating 
PD and other anxiety disorders is addressed by Roy-Byrne 
and Cowley (2002). While several tricyclic antidepressants 
are effective treatments for PD with or without agoraphobia, 
their use is limited by their side effects.
A meta-analysis including 43 studies (Bakker et al 2002) 
compared the short-term efﬁ  cacy of selective serotonin reuptake 
inhibitors vs tricyclic antidepressants in the treatment of PD. 
Outcome was measured with the proportion of patients becom-
ing panic-free, and with pre/post Cohen’s d effect sizes, calcu-
lated for four clinical variables: panic, agoraphobia, depression, 
and general anxiety. There were no differences between SSRIs 
and TCAs on any of the effect sizes, indicating that both groups 
of antidepressants are equally effective in reducing panic symp-
toms, agoraphobic avoidance, depressive symptomatology and 
general anxiety. In addition, the percentage of patients free of 
panic attacks at post-test did not differ. The number of drop 
outs, however, was signiﬁ  cantly lower in the group of patients 
treated with SSRIs. The authors conclude that SSRIs and TCAs 
are equal in efﬁ  cacy in the treatment of PD, but SSRIs are tol-
erated better. In a study by Mavissakalian (2003), imipramine 
was found to act more rapidly than sertraline, but there was no 
difference in efﬁ  cacy between the two drugs at week 8. Side 
effects were more frequent with imipramine.
Monoamine oxidase inhibitors
Beneﬁ  t and side effects of irreversible MAO inhibitors as 
well as of reversible ones for treating PD and other disorders 
have been reported (Riederer et al 2004).
While several irreversible MAO inhibitors are effective 
treatments for PD with or without agoraphobia, their use is Neuropsychiatric Disease and Treatment 2008:4(4) 781
Panic disorder
limited by their side effects and by their interactions with 
other drugs and food components. Selective and reversible 
MAO-A inhibitors (RIMAs) exempliﬁ  ed by moclobemide and 
brofaromine do not require dietary restrictions, have fewer 
drug interactions than irreversible MAO inhibitors, and are bet-
ter tolerated. In  2 comparative trials (Kruger and Dahl 1999; 
Tiller et al 1999), moclobemide was found to be as efﬁ  ca-
cious as ﬂ  uoxetine or clomipramine in the treatment of PD 
with or without agoraphobia and to have no serious side 
effects. In 2 comparative trials (Bakish and al 1993; Van 
Vliet et al 1996), brofaromine was found to be as efﬁ  cacious 
as clomipramine or ﬂ  uvoxamine and to have no serious 
side effects.
Selective serotonin reuptake inhibitors 
(Table 1)
During the past 10 years, SSRIs have emerged as ﬁ  rst-line 
pharmacological treatments for PD with or without ago-
raphobia. Six SSRIs are effective and well-tolerated short 
term treatments of PD: ﬂ  uvoxamine, paroxetine, ﬂ  uoxetine, 
sertraline, citalopram, and escitalopram.
Fluvoxamine
In a study by Black and colleagues (1993), patients with 
moderate to severe PD were randomly assigned to receive 
8 weeks of ﬂ  uvoxamine, cognitive therapy, or placebo. 
At the main comparison point, 57% of patients receiving 
ﬂ  uvoxamine were rated moderately improved or better vs 
40% of the group given cognitive therapy and 22% of the 
placebo-treated group. At that point, 43% of the ﬂ  uvoxamine 
recipients vs 25% of cognitive therapy and 4% of placebo 
recipients were free of panic attacks. Hoehn-Saric et al (1993) 
compared ﬂ  uvoxamine with placebo in 50 PD patients, using 
an 8-week, double-blind, parallel-groups design. At the end 
of the study, signiﬁ  cantly more patients on ﬂ  uvoxamine 
were free of major and minor panic attacks than those on 
placebo. A double-blind, placebo-controlled, multicenter trial 
involving 54 outpatients (Bakish et al 1996) compared the 
efﬁ  cacy, tolerability, and safety of ﬂ  uvoxamine, imipramine, 
and placebo in the treatment of PD with or without agora-
phobia. Fluvoxamine was more effective than placebo and 
as effective as imipramine in reducing spontaneous panic 
attacks in moderate to severe PD. An 8-week multicenter, 
double-blind, placebo-controlled study in outpatients (Asnis 
et al 2001) compared ﬂ  uvoxamine with placebo in patients 
with DSM-III-R deﬁ  ned PD with or without agoraphobia. 
Fluvoxamine produced highly signiﬁ  cant improvements in 
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most measures of the frequency and severity of PD and in 
the more global aspects of disability and distress.
Paroxetine
In a randomized, double-blind, placebo-controlled study 
(Oehrberg et al 1995), patients received 12 weeks of treatment 
with paroxetine (20, 40, or 60 mg) or placebo. Analysis of 
the results showed statistically signiﬁ  cant differences in favor 
of paroxetine between the two treatment groups in 2 primary 
measures of outcome, ie, 50% reduction in total number of 
panic attacks and number of panic attacks reduced to one or 
zero over the study period. In a 12-week, double-blind, par-
allel group, placebo-controlled study, Lecrubier et al (1997) 
compared paroxetine with clomipramine in 367 patients with 
DSM-III-R deﬁ  ned PD. Paroxetine produced signiﬁ  cant 
improvements compared with placebo in various measure-
ments of panic attack frequency, and was as effective as 
clomipramine. In a large, double-blind, ﬁ  xed-dose, placebo-
controlled, multicenter study of paroxetine in the treatment 
of PD (Ballenger et al 1998), patients were assigned to 10, 
20, or 40 mg/day of study medication. At week 10, 86% of 
the patients taking 40 mg/day, 65.2% of those taking 20 mg, 
67.4% of those taking 10 mg, and 50.0% of the placebo-treated 
patients were free of full panic attacks.
Sheehan et al (2005) compared controlled-release (CR) 
paroxetine with placebo in patients with DSM-IV PD with 
or without agoraphobia in 3 large, identical, double-blind, 
placebo-controlled, 10-week clinical trials that were pooled 
for analysis. Paroxetine CR was statistically superior to 
placebo in the primary outcome measure, ie, percentage of 
patients who were free of panic attacks in the 2 weeks prior 
to endpoint. Of the total population that completed or pre-
maturely terminated treatment, 63% and 53% of paroxetine 
CR- and placebo-treated patients, respectively, were panic-
free during the ﬁ  nal 2 weeks. For week 10 completers (72% 
of total), 73% and 60% of paroxetine CR- and placebo-treated 
patients, respectively, were panic-free at week 10.
Fluoxetine
In a randomized controlled study of fluoxetine versus 
placebo (Michelson et al 1998), patients with a diagnosis 
of PD were randomly assigned to treatment with 10 or 20 
mg/day of ﬂ  uoxetine or placebo. Fluoxetine, particularly the 
20 mg/day dose, was associated with more improvement than 
was placebo in patients with PD across multiple symptom 
measures, including global improvement, total panic attack 
frequency, phobic symptoms, and functional impairment. 
In another randomized, placebo-controlled trial (Michelson 
et al 2001), patients with PD were randomized to placebo 
or to ﬂ  uoxetine initiated at 10 mg daily for 1 week and then 
increased to 20 mg daily. The trial lasted 12 weeks, but after 
6 weeks patients who had failed to achieve a satisfactory 
response were eligible for dose escalation to a maximum of 
60 mg of ﬂ  uoxetine daily. The results showed that ﬂ  uoxetine 
at a dose of 20 mg daily was associated with a statistically 
signiﬁ  cantly greater proportion of panic-free patients com-
pared with placebo after 6 weeks and at end-point.
Sertraline
In a ﬂ  exible-dose multicenter trial (Pollack et al 1998), 176 non-
depressed outpatients with PD, with or without agoraphobia, 
from 10 sites followed identical protocols that used a ﬂ  exible-
dose design. Patients were randomly assigned to 10 weeks of 
double-blind, ﬂ  exible-dose treatment with either sertraline 
hydrochloride (50–200 mg) or placebo. Sertraline-treated 
patients exhibited signiﬁ  cantly greater improvement at end 
point than did patients treated with placebo for panic attack fre-
quency. In a multisite, double-blind, placebo-controlled, ﬁ  xed-
dose investigation (Londborg et al 1998), 178 out-patients 
with PD were randomly assigned to 12 weeks of double-blind 
treatment with sertraline (50, 100, or 200 mg) or placebo. 
Sertraline was superior to placebo in reducing the number of 
panic attacks, situational attacks, unexpected attacks, limited 
symptom attacks, and time spent worrying. Higher doses were 
no more effective than the 50 mg dose.
In a randomized, double-blind, parallel-group, ﬂ  exible-
dose comparison of sertraline and placebo in outpatients with 
a DSM-III-R diagnosis of PD with or without agoraphobia 
(Pohl et al 1998), sertraline was signiﬁ  cantly more effective 
than placebo in decreasing the number of full and limited-
symptom panic attacks. Sheikh and colleagues (2000) pooled 
data from 2 ﬁ  xed-dose studies. Patients meeting DSM-III-R 
criteria for moderate-to-severe PD with or without ago-
raphobia were randomized sertraline (50 mg, 100 mg, or 
200 mg). All three sertraline doses produced signiﬁ  cant 
efﬁ  cacy compared with placebo, with no consistent evidence 
of a dose-response effect. In a double-blind comparison 
(Bandelow et al 2004), adult outpatients with PD with or 
without agoraphobia were randomly assigned to 12 weeks 
of treatment with ﬂ  exible doses of sertraline (50–150 mg) 
or paroxetine (40–60 mg). Sertraline and paroxetine had 
equivalent efﬁ  cacy in PD.
Citalopram and escitalopram
In a double-blind, placebo and clomipramine controlled, 
parallel group 8-week study (Wade et al 2000), a total of Neuropsychiatric Disease and Treatment 2008:4(4) 784
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475 patients with PD, with or without agoraphobia, were 
randomized to treatment with either placebo, clomipramine 
60 or 90 mg/day, or citalopram 10 or 15 mg/day, or 20 or 
30 mg/day, or 40 or 60 mg/day. Treatment with citalopram 
at 20 or 30 mg, 40 or 60 mg and clomipramine were sig-
niﬁ  cantly superior to placebo, judged by the number of 
patients free of panic attacks in the week prior to the ﬁ  nal 
assessment. All rating scales examined suggested that 
citalopram 20 or 30 mg was more effective than citalopram 
40 or 60 mg.
A randomized, double-blind, placebo-controlled trial 
of 366 subjects (128 escitalopram patients, 119 citalopram 
patients, and 119 placebo patients) conducted by Stahl et al 
(2003) showed that escitalopram is efﬁ  cacious, safe, and well 
tolerated in the treatment of PD. The rate of discontinuation 
for adverse events was 6.3% for escitalopram, 8.4% for 
citalopram, and 7.6% for placebo.
Serotonin norepinephrine 
reuptake inhibitors (Table 2)
Among the class of SNRIs, venlafaxine and venlafaxine 
extended-release (ER) have been shown to be effective in 
the acute treatment of PD with or without agoraphobia. 
A small 8-week, double-blind, placebo-controlled study 
(Pollack et al 1996) investigated the efﬁ  cacy of venlafaxine 
for the treatment of PD. Patients treated with venlafaxine 
experienced significantly greater global improvement 
than those on placebo and exhibited trends toward greater 
improvement on anxiety and depression symptoms as 
assessed by the Hamilton rating scales.
In a double-blind, placebo-controlled study (Bradwejn 
et al 2005), 361 adult out-patients with PD were randomly 
assigned to receive venlafaxine ER (75–225 mg/day) 
or placebo for up to 10 weeks in a double-blind study. 
Venlafaxine ER was not associated with a greater proportion 
of patients free from full-symptom panic attacks at the 
ﬁ  nal on-therapy evaluation, but was associated with lower 
mean panic attack frequency and a higher proportion free 
from limited-symptom panic attacks, higher response and 
remission rates, and improvements in anticipatory anxiety, 
fear and avoidance. Pollack et al (2007) compared the efﬁ  -
cacy of venlafaxine ER (75 mg/day or 150 mg/day), and 
paroxetine (40 mg/day) with placebo in adult outpatients 
who met DSM-IV criteria for PD with or without agora-
phobia. No signiﬁ  cant differences were observed between 
active treatment groups. Panic-free rates at end point with 
active treatment ranged from 54% to 61%, compared with 
35% for placebo. Approximately 75% of patients given 
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active treatment were responders, and nearly 45% achieved 
remission.
Benzodiazepines
Benzodiazepines such as lorazepam (Schweitzer et al 1990), 
alprazolam (Verster and Volkerts 2004),) and clonazepam 
(Rosenbaum 2004) are effective treatments for PD with or 
without agoraphobia, alone or in combination with one of 
the SSRIs.
Issues in the clinical use of high-potency benzodiaz-
epines such as lorazepam, alprazolam, and clonazepam 
for treating PD with or without agoraphobia have been 
discussed in a review article by Chouinard (2004). High-
potency benzodiazepines are effective in treating PD and 
panic attacks with or without agoraphobia, alone or as 
add-on therapy to selective serotonin reuptake inhibitors. 
Although as a class benzodiazepines act rapidly and are 
well tolerated, their use presents clinical issues such as 
dependence, rebound anxiety, memory impairment, and 
discontinuation syndrome.
As noted by Pollack et al (2003), combining benzodiaz-
epine and antidepressant agents early in treatment offers the 
potential of accelerating response compared with antidepres-
sant monotherapy and the possibility of additive or synergistic 
effects from the two classes of agents, but there has been rela-
tively little systematic assessment of the safety and efﬁ  cacy of 
this therapeutic strategy. These authors report the results of a 
randomized, double-blind, 3-arm study in patients with PD, 
comparing the efﬁ  cacy and safety of paroxetine and placebo, 
paroxetine coadministered with clonazepam followed by a 
tapered benzodiazepine discontinuation phase, and ongoing 
combination treatment. All treatment groups demonstrated 
signiﬁ  cant improvement by endpoint. There was a signiﬁ  -
cant advantage for the combined treatment groups early in 
treatment but, subsequently, outcome in all three groups 
was similar. The combined treatment with paroxetine and 
clonazepam resulted in more rapid response than with the 
SSRI alone, but there was no differential beneﬁ  t beyond the 
initial few weeks of therapy.
Bearing in mind that pharmacological treatment guide-
lines for PD have changed as newer treatment options have 
become available, Bruce et al (2003) examined how the use 
of psychotropic drugs in patients with PD with or without 
agoraphobia has shifted over the course of 10 years. A total 
of 443 patients with PD were interviewed to examine 
their use of psychotropic medications. Treatment patterns 
for psychotropic drugs appeared to have remained stable 
over the past decade, with benzodiazepines being the most 
commonly used medication for PD. These results highlight 
a gap between pharmacological treatment guidelines and 
actual delivery of care.
Long-term pharmacological 
treatment
There has been little systematic work done regarding the 
long-term treatment of PD with or without agoraphobia, and 
data on the prophylactic effectiveness of maintenance treat-
ment are still limited, as well as information on the risk of 
relapse due to discontinuation of pharmacological treatment 
after an initial response to acute therapy.
Maintenance treatment (Table 3)
Lecrubier and Judge (1997) studied the longer term effects of 
continuous paroxetine or clomipramine treatment in patients 
with DSM-III-R deﬁ  ned PD. Patients who satisfactorily 
completed a 12-week, double-blind, placebo-controlled 
study of paroxetine and clomipramine could choose to 
continue receiving their randomized treatment for a further 
36 weeks. Paroxetine and clomipramine were signiﬁ  cantly 
more effective than placebo throughout the long-term study 
in reduction from baseline of full panic attacks, and at the 
end of treatment in the proportion of patients who eventu-
ally experienced no panic attacks. There were no signiﬁ  cant 
differences between paroxetine and clomipramine. Not only 
was efﬁ  cacy maintained, but continued improvement was 
also seen, indicating the importance of long-term treatment 
in patients with PD.
A controlled, prospective, double-blind, long-term 
treatment study of citalopram (Lepola et al 1998) fol-
lowed patients for 1 year. Patients were assigned to 1 of 
3 ﬁ  xed dosage ranges of citalopram, 1 dosage range of 
clomipramine, or placebo. After an 8-week acute treat-
ment period, patients could continue the treatment for up 
to 1 year. Of the 475 patients who were randomly assigned 
for the short-term trial, 279 agreed to continue double-
blind treatment at their assigned doses. In all drug-treated 
groups, except the group receiving the lowest citalopram 
dose, the treatment outcome was generally better than with 
placebo. As determined by a life table analysis of response, 
the probability of response during the 12 months was sig-
niﬁ  cantly greater with all treatment regimens than with 
placebo, with citalopram 20 or 30 mg/day demonstrating 
the best response.
In a study by Michelson et al (1999), patients who 
responded to acute ﬂ  uoxetine treatment were randomized 
to 24 weeks of continued ﬂ  uoxetine or placebo. Fluoxetine Neuropsychiatric Disease and Treatment 2008:4(4) 786
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responders randomized to continue on their acute-phase 
fluoxetine dose experienced statistically significant 
improvement in panic attack frequency and phobia rating 
scale score over 24 weeks of therapy, while those switched 
to placebo experienced statistically signiﬁ  cant worsening 
in Hamilton Anxiety (HAM-A), Hamilton Depression 
(HAM-D), and SCL-90-R rating scores.
Discontinuation
According to Roy-Byrne and Cowley (2002), many studies 
show clearly that discontinuation of medication results in 
relapse in a substantial proportion of patients, with rates of 
25%–50% recorded within 6 months, depending on study 
design. With reference to a study by Rickels and colleagues 
(1993), the same authors state that, in addition, SSRIs, SNRIs, 
tricyclic antidepressants, and benzodiazepines are associated 
with a time-limited withdrawal syndrome.
Mavissakalian and Perel (1999) have assessed the 
12-month cumulative risk of relapse speciﬁ  cally due to 
discontinuation of imipramine and tested the hypothesis that 
maintenance treatment with imipramine protects patients 
with PD and agoraphobia from such reversals. After an 
acute-phase open trial with imipramine (2.25 mg/kg daily) 
for 6 months, 56 patients who were in stable remission 
were randomly assigned to double-blind maintenance or 
discontinuation conditions. Patients were then followed with 
planned assessments every 2 months during a 1-year period. 
Maintenance treatment (1 relapse) and discontinuation (10 
relapses) conditions had signiﬁ  cantly different survival 
curves. The results conﬁ  rm the very high degree of prophy-
lactic effectiveness of maintenance imipramine treatment 
and conﬁ  rm that relapse is substantial after discontinuation 
of treatment.
Mavissakalian and Perel (2002) further explored 
the relationship between relapse and duration of imipramine 
treatment in PD with or without agoraphobia. Fifty-
one patients, all in remission at the end of six months 
acute phase open trial with imipramine 2.25 mg/kg/day, 
and randomized to double-blind maintenance or placebo 
substitution, discontinued imipramine treatment eventu-
ally and were followed over a 12-month risk period: 
27 during ﬁ  rst year placebo substitution, 7 after 12 months 
of imipramine maintenance in placebo substitution, and 
17 after variable durations of imipramine maintenance in 
open discontinuation. The rate of relapse after only 6 months 
of treatment (10 out of 27, 37%) was identical to the rate 
of relapse after 12–30 months of treatment (9 out of 24, 
37.5%). The results suggest a lack of speciﬁ  c protective Neuropsychiatric Disease and Treatment 2008:4(4) 787
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effects beyond prophylaxis and underscore the difﬁ  culty in 
predicting relapse in fully remitted PD with agoraphobia 
patients.
Two 3-year naturalistic, uncontrolled, non-randomized 
outcome studies have yielded divergent results. Toni et al (2000) 
have reported on systematic data from a 3-year naturalistic 
prospective study on 336 patients with PD with or without 
agoraphobia treated with antidepressants in a setting of rou-
tine clinical practice. The antidepressants used were mainly 
imipramine, clomipramine, and paroxetine. Of those patients 
who interrupted the treatment, only 38% stayed in remission. 
Relapses after a period of at least 2 months of complete remis-
sion were also common, and the probability of presenting at 
least 1 relapse during the 3-year follow-up period was 67.1% 
for PD and 39% for agoraphobia.
In a study by Dannon et al (2004), 143 patients with PD, 
with or without agoraphobia, who had responded to a 12-week 
trial of paroxetine treatment, continued to receive paroxetine 
maintenance therapy for a total of 12 months or 24 months. 
After the period of maintenance treatment, patients were 
monitored throughout a 1-year discontinuation follow-up 
phase. Only 21 of 143 patients (14%) relapsed during the 
1-year medication discontinuation follow-up phase. There 
were no signiﬁ  cant differences in relapse rates between the 
patients who received intermediate-term (12 months) and 
those who chose the long term course (24 months) paroxetine 
treatment.
Cognitive behavioral therapy 
and combination treatments
Cognitive behavioral therapy (CBT) for PD with or without 
agoraphobia usually combines cognitive restructuring with 
interoceptive exposure and with progressive exposure to 
places and situations from which escape might be difﬁ  cult 
(or embarrassing), or in which help may not be available in 
the event of having a panic attack or panic-like symptoms. 
The efﬁ  cacy of CBT for the treatment of PD as well as for 
agoraphobia has been established in a number of randomized 
controlled trials.
Cognitive behavioral therapy
In an early meta-analysis of treatment outcome for PD, 
Gould et al (1995) compared cognitive interventions with 
exposure treatments and various control conditions. CBT 
treatments in general had the highest effect size compared 
with pharmacological treatments or combination treatments. 
The CBT treatment showed virtually no slippage in effect 
size by 1-year follow-up compared with sizable slippage 
for pharmacological treatment. Importantly, there was also 
a signiﬁ  cantly lower attrition rate among CBT treatments 
compared with pharmacological treatments.
According to 2 recent meta-analyses by Westen et al 
(2005) and Mitte et al (2005), rates of patients who are 
panic-free or meet criteria for recovery and high end-state 
functioning after treatment with CBT compare well with 
pharmacotherapy, with evidence that CBT is at least as 
effective as pharmacotherapy, with strong tolerability, main-
tenance of treatment gains, cost efﬁ  cacy, improvements in 
comorbid conditions, and quality of life.
In a recent review, Roy-Byrne et al (2006) concluded that 
the nature of the evidence concerning the efﬁ  cacy of CBT 
is robust, but that CBT approaches are underused in most 
countries, compared with drug treatment. According to the 
same authors, low rates of use are probably due to public 
unfamiliarity with the nature and efﬁ  cacy of CBT relative 
to medication, to restricted access to professionals who are 
familiar with its efﬁ  cacy and delivery, and to little training 
and familiarity with CBT for many mental-health profes-
sionals who currently treat patients with PD.
The empirical status of CBT for a wide range of disor-
ders, including CBT for PD with or without agoraphobia, 
has also been reviewed recently by Butler et al (2006). 
According to the authors, the outcome ﬁ  ndings on CBT 
for PD are supportive and robust. In addition, the authors 
state that there appears to be robust and convergent meta-
analytic evidence that CBT produces vastly superior long-
term persistence of effects, with relapse rates half those of 
pharmacotherapy.
A recent study by Craske et al (2006) raises the possi-
bility that remaining focused on CBT for PD may be more 
beneﬁ  cial for both principal and comorbid diagnoses than 
combining CBT for PD with “straying” to CBT for co-morbid 
disorders.
Treatments combining 
pharmacotherapy and CBT
A substantial proportion of patients does not fully respond 
or responds poorly to either pharmacotherapy or CBT alone. 
Since both types of treatment may be effective, it seems rea-
sonable to expect that their combination might enhance the 
efﬁ  cacy of either treatment when administered alone. In fact, 
as pointed out in reviews by Otto et al (2005) and Pull (2006, 
2007), empirical data suggest a complex relationship between 
pharmacotherapy and CBT and highlight the need for more 
extensive studies, concerning, in particular, the long-term 
efﬁ  cacy and effectiveness of combination treatments and the Neuropsychiatric Disease and Treatment 2008:4(4) 788
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effect of discontinuation of either treatment after combined 
treatment.
Combination treatments for PD with or without agoraphobia 
have been examined in a number of randomized controlled 
trials over the past 20 years. Two recent meta-analyses 
summarize the evidence concerning the short- and long-term 
beneﬁ  ts and adverse effects of combining pharmacotherapy 
with CBT versus administrating either treatment alone.
A meta-analysis of the efﬁ  cacy of psychotherapy and 
pharmacotherapy in PD with and without agoraphobia by 
Mitte (2005) included 124 studies. Twenty studies provided 
data on the efﬁ  cacy of psychotherapy compared with a com-
bination of psychotherapy and pharmacotherapy. There was a 
signiﬁ  cantly higher effect size for the combination approach 
for post-test. In contrast, for follow-up (half of the studies 
included a follow-up), there was no signiﬁ  cant difference 
in efﬁ  cacy between CBT alone and a combination approach 
associating CBT and pharmacotherapy.
In a systematic and comprehensive search for relevant 
trials, Furukava et al (2006) identiﬁ  ed 21 studies comparing 
a combination of psychotherapy (with one exception, the 
psychotherapy administered in the studies was CBT) and 
antidepressant pharmacotherapy with either treatment alone. 
The authors applied the intention-to-treat principle in their 
analyses (meta-analyses and meta-regressions) by counting 
all of the drop outs as non-responders. The typical length of 
the acute-phase active treatment was between 8 and 12 weeks. 
Nine studies included a follow-up extending over a period of 
6–24 months after termination of acute phase and continua-
tion treatments. In the acute phase treatment, the combined 
therapy was superior to antidepressant pharmacotherapy or 
psychotherapy alone. After termination of the acute phase 
treatment, the combined therapy was still more effective 
than pharmacotherapy alone but no longer more effective 
than psychotherapy alone. For the comparison between the 
combination therapy and antidepressant pharmacotherapy, 
the combination therapy was found to have no disadvantage 
in the long term, ie, there was no evidence for long-term 
deleterious effects of combined treatments. For the com-
parison between combination therapy and psychotherapy, 
there was no evidence of long-term beneﬁ  t of the former 
with the latter, ie, combination treatments were not more 
effective than CBT alone. The authors conclude that either 
combined therapy or CBT alone may be chosen as ﬁ  rst-line 
treatment for PD with or without agoraphobia, depending on 
the patient’s preferences.
According to a recent study, the addition of CBT to medi-
cation may be associated with less severe side effects and 
fewer dropouts due to perceived side effects than treatment 
with medication alone. Marcus et al (2007) assessed whether 
adding CBT to imipramine for patients with PD decreased 
the severity of side effects and dropouts from side effects. 
Data were analyzed for 172 PD patients who were randomly 
assigned to receive imipramine alone, imipramine plus CBT, 
or placebo. Patients treated with imipramine plus CBT 
experienced less severe fatigue/weakness, dry mouth, and 
sweating and had a lower rate of dropout due to side effects 
compared with those treated with imipramine only.
Novel combination strategies
Three novel combination strategies have recently been 
explored in the treatment of PD with or without agoraphobia: 
the sequential use of pharmacotherapy and CBT, the 
combination of virtual reality exposure therapy with CBT, 
and the use of cognitive enhancers such as d-cycloserine in 
combination with CBT.
Sequential use of pharmacotherapy 
and CBT (Table 4)
Fava et al (2005) have reviewed clinical trials in which treat-
ment components were used in a sequential order, ie pharma-
cotherapy followed by psychotherapy, psychotherapy followed 
by pharmacotherapy, one drug treatment after another, or one 
psychotherapeutic technique after another. According to the 
authors, the sequential use of pharmacotherapy and CBT 
introduces a conceptual shift in current treatment approaches 
of mood and anxiety disorders. It is an intensive, 2-stage 
approach, which is based on the fact that one course of treat-
ment with a speciﬁ  c treatment (whether pharmacotherapy or 
psychotherapy) is unlikely to entail the solution to the complex 
array of symptoms of patients with these disorders.
In the review by Fava et al (2005) the sequential use 
of pharmacotherapy and psychotherapy was not found to 
improve long-term outcome in anxiety disorders. In contrast, 
2 recent randomized, double-blind, placebo-controlled study 
do suggest that patients with PD who are unsuccessfully 
treated with initial CBT may in fact beneﬁ  t from the addition 
of an SSRI as a second treatment modality and vice versa.
In a randomized, double-blind, placebo-controlled study 
Kampman et al (2002) examined the effects of adjunctive 
paroxetine in PD patients unsuccessfully treated with CBT 
alone. 161 patients with PD with or without agoraphobia 
underwent a manual-guided CBT of 15 sessions. Forty-three 
unsuccessfully treated patients from this group were included 
in a double-blind, placebo-controlled, next-step treat-
ment study consisting of continued CBT plus adjunctive Neuropsychiatric Disease and Treatment 2008:4(4) 789
Panic disorder
T
a
b
l
e
 
4
 
S
e
q
u
e
n
t
i
a
l
 
u
s
e
 
o
f
 
p
h
a
r
m
a
c
o
t
h
e
r
a
p
y
 
a
n
d
 
C
B
T
S
t
u
d
y
D
e
s
i
g
n
n
M
e
a
s
u
r
e
s
T
r
e
a
t
m
e
n
t
t
R
e
s
u
l
t
s
K
a
m
p
m
a
n
 
e
t
 
a
l
 
(
2
0
0
2
)
N
e
x
t
-
s
t
e
p
,
 
r
a
n
d
o
m
i
z
e
d
,
 
d
o
u
b
l
e
-
b
l
i
n
d
,
 
p
l
a
c
e
b
o
-
c
o
n
t
r
o
l
l
e
d
1
6
1
A
g
o
r
a
p
h
o
b
i
c
 
b
e
h
a
v
i
o
r
 
a
n
d
 
a
n
x
i
e
t
y
 
d
i
s
c
o
m
f
o
r
t
M
a
n
u
a
l
-
g
u
i
d
e
d
 
C
B
T
 
o
f
 
1
5
 
s
e
s
s
i
o
n
s
 
+
 
p
a
r
o
x
e
t
i
n
e
 
4
0
 
m
g
/
d
a
y
 
o
r
 
p
l
a
c
e
b
o
1
5
 
s
e
s
s
i
o
n
s
C
B
T
 
+
 
p
a
r
o
x
e
t
i
n
e
 

 
C
B
T
 
+
 
p
l
a
c
e
b
o
 
p
 

 
0
.
0
5
H
e
l
d
t
 
e
t
 
a
l
 
(
2
0
0
6
)
O
p
e
n
 
n
e
x
t
-
s
t
e
p
 
t
r
e
a
t
m
e
n
t
 
s
t
u
d
y
6
3
C
G
I
,
 
P
a
n
i
c
 
I
n
v
e
n
t
o
r
y
,
 
H
A
M
-
A
:
 
b
a
s
e
l
i
n
e
,
 
1
2
t
h
 
w
e
e
k
l
y
 
s
e
s
s
i
o
n
,
 
1
-
y
e
a
r
 
p
o
s
t
 
t
r
e
a
t
m
e
n
t
E
x
i
s
t
i
n
g
 
v
a
r
i
o
u
s
 
p
h
a
r
m
a
c
o
l
o
g
i
c
a
l
 
t
r
e
a
t
m
e
n
t
 
+
 
1
2
 
s
e
s
s
i
o
n
s
 
o
f
 
C
B
T
4
 
m
o
n
t
h
s
R
e
d
u
c
t
i
o
n
 
i
n
 
b
o
t
h
 
a
n
t
i
d
e
p
r
e
s
s
a
n
t
s
 
a
n
d
 
b
e
n
z
o
d
i
a
z
e
p
i
n
e
 
u
s
e
 
(
p
 

 
0
.
0
0
1
)
 
a
c
r
o
s
s
 
t
r
e
a
t
m
e
n
t
 
a
n
d
 
f
o
l
l
o
w
-
u
p
paroxetine at a dose of 40 mg/day or continued CBT plus 
placebo. Overall, patients in the CBT plus paroxetine con-
dition improved signiﬁ  cantly on agoraphobic behavior and 
anxiety discomfort, whereas patients in the CBT plus placebo 
condition did not.
Heldt et al (2006) reported the results of an open next-step 
treatment study involving 63 patients who completed group 
CBT for PD after failing to respond adequately to previous 
pharmacotherapy. All patients had been undergoing phar-
macological treatment for PD at the time of treatment, with 
a mean duration of pharmacotherapy of 3 years. In order to 
be part of the study, patients had to have residual symptoms 
of PD with or without agoraphobia, such as panic attacks, 
anticipatory anxiety, and phobic avoidance despite being on 
a stable dose of medications for at least 4 months. Patients 
were treated in 1 of 9 groups (with a mean of 7 patients per 
group) during 12 sessions of CBT provided over 4 months by 
2 therapists. Signiﬁ  cant reductions in symptoms were evident 
for all outcome measures (frequency of panic attacks, agora-
phobia and anticipatory anxiety) with maintenance of these 
gains at 1-year follow-up. Follow-up after 1 year showed 
signiﬁ  cant beneﬁ  t on all dimensional outcome scores, and 
nearly two-thirds of the sample met remission criteria.
The combination of virtual reality 
exposure therapy and CBT
Recent studies provide evidence that virtual reality exposure 
therapy (VRET) is a promising tool for the treatment of sev-
eral anxiety disorders. As shown in a review by Pull (2005), 
the efﬁ  cacy of standard treatments of anxiety disorders may 
be signiﬁ  cantly enhanced using virtual reality exposure 
therapy. Most studies in the ﬁ  eld have been on speciﬁ  c 
phobias, in particular on fear of ﬂ  ying, acrophobia, fear of 
driving, claustrophobia, and fear of spiders. In addition, sev-
eral studies have been published on the use of virtual reality 
exposure therapy for social anxiety disorder, posttraumatic 
stress disorder and PD with or without agoraphobia.
In an ongoing, randomized controlled study by Botella 
et al (2004a, 2004b), patients with or without agoraphobia 
are assigned to either VRET, to exposure in vivo, or to a 
waiting list control group. Initial results of the study indicate 
that patients in the VRET and in the CBT groups improve 
signiﬁ  cantly more than patients in the waiting list control 
group, and that there are no signiﬁ  cant differences in outcome 
measures between patients treated by VRET and patients 
treated by exposure in vivo.
Another ongoing randomized controlled investigation 
involving the Collège de France and 3 university hospitals Neuropsychiatric Disease and Treatment 2008:4(4) 790
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Figure 1 Virtual reality environments are presented using a head mounted display and tracking head movement.
(in Luxembourg, Lyon, and Paris) compares the efﬁ  cacy 
of traditional CBT, VRET, and a waiting list in patients 
meeting DSM-IV criteria for PD with agoraphobia (Pull 
et al 2006). CBT and VRET are given in 12 sessions of 
90 minutes’ duration. Both types of treatment are provided 
by the same clinicians who are experienced therapists. 
CBT includes respiratory control, cognitive restructuring, 
exposure in imagination to anxiety provoking scenes and 
interoceptive exposure to anxiety-related physical sensa-
tions, and homework involving exposure to real-life situa-
tions. VR environments are presented using a head mounted 
display and tracking head movement (Kaiser Electro-Optics 
Proview 60™, Germany) (Figure 1). VRET includes expo-
sure to 12 virtual environments (taking a subway, walking 
in a tunnel, taking an elevator, shopping in a supermarket, 
driving a car on a lonely country road, traveling by plane, 
entering a movie theatre, driving a car in a city, driving 
a car in a tunnel, traveling by bus, walking in a crowd, 
being caught in a sensorial conﬂ  ict) provoking a feeling 
of derealization. Initial results of the study indicate that 
there are no signiﬁ  cant differences in outcome measures 
between patients treated by VRET and patients treated by 
traditional CBT.
The combination of cognitive 
enhancers and CBT (Table 5)
The ﬁ  rst cognitive enhancer to be used in addition to CBT in 
the treatment of anxiety disorders is D-cycloserine (DCS), 
a partial agonist at the N-methyl-d-aspartate receptor that 
has previously been shown to improve extinction of fear in 
rodents. As fear reduction in exposure therapy is similar to 
extinction learning, DCS has been used recently in 2 inves-
tigations, one for the treatment of acrophobia, the other the 
treatment of social phobia, to determine whether DCS will 
also improve extinction of fear in human phobic patients 
undergoing behavioral exposure therapy. The pilot data 
provide initial support for the use of acute dosing of DCS as 
an adjunct to exposure-based psychotherapy to accelerate the 
associative learning processes that contribute to correcting 
the psychopathology of anxiety disorders.
Ressler et al (2004) enrolled 28 subjects with acropho-
bia in a randomized, double-blind, placebo-controlled trial Neuropsychiatric Disease and Treatment 2008:4(4) 791
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examining DCS versus placebo treatment in combination 
with a precisely controlled exposure paradigm. Subjects 
were treated with 2 sessions of behavioral exposure therapy 
using virtual reality exposure to heights within a virtual glass 
elevator. Single doses of placebo or DCS were taken prior 
to each of the 2 sessions of virtual reality exposure therapy. 
Subjects, therapists, and assessors were blind to the treat-
ment condition. Subjects returned at 1 week and 3 months 
post-treatment for measures to determine the presence and 
severity of acrophobia symptoms. Included were measures 
of acrophobia within the virtual environment, measures of 
acrophobia in the real world, and general measures of overall 
improvement. An objective measure of fear, electrodermal 
skin ﬂ  uctuation, was also included during the virtual expo-
sure to heights. Symptoms were assessed by self report and 
by independent assessors at approximately 1 week and 3 
months post-treatment.
Exposure therapy combined with DCS resulted in 
signiﬁ  cantly larger reductions of acrophobia symptoms on 
all main outcome measures. Subjects receiving DCS had 
signiﬁ  cantly more improvement compared with subjects 
receiving placebo within the virtual environment (1 week 
after treatment and 3 months later). Subjects receiving DCS 
also showed signiﬁ  cantly greater decreases in post-treatment 
skin conductance ﬂ  uctuations during the virtual exposure. 
Additionally, subjects receiving DCS had significantly 
greater improvement compared with subjects receiving 
placebo on general measures of real-world acrophobia symp-
toms (acrophobia avoidance, acrophobia anxiety, attitudes 
toward heights, clinical global improvement, and number 
of self exposures to real world heights). The improve-
ment was evident early in treatment and was maintained at 
3 months.
Preliminary support for the use of short-term dosing 
of d-cycloserine as an adjunctive intervention to exposure 
therapy has also emerged from a study on social anxiety 
disorder. In a randomized controlled study by Hofmann et al 
(2006), participants suffering from social anxiety disorder 
received 5 therapy sessions delivered in either an individual 
or group therapy format. The first session provided an 
introduction to the treatment model and was followed by 
4 sessions emphasizing exposure to increasingly challeng-
ing public speech situations with videotaped feedback of 
performances. One hour prior to each session, participants 
received single doses of d-cycloserine or placebo. Symptoms 
were assessed before treatment, after treatment, and 1 month 
after the last session by patient self report and by clinicians 
blind to the randomization condition. Participants receiving 
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d-cycloserine in addition to exposure therapy reported 
signiﬁ  cantly less social anxiety compared with patients 
receiving exposure therapy plus placebo. Controlled effect 
sizes were in the medium to large range.
Primary care interventions (Table 6)
PD with or without agoraphobia is highly prevalent in primary 
care. During the past few years, several studies have assessed 
the effectiveness of new treatment approaches in primary care 
settings. Several interventions, including collaborative care 
and combined CBT and pharmacotherapy tailored for primary 
care physicians, have been shown to be more effective than 
usual care at improving anxiety symptoms, health-related 
quality of life, and work-related outcomes.
In a randomized controlled study by Rollman et al 
(2003), patients with PD with or without agoraphobia and 
patients with generalized anxiety disorder were randomly 
assigned to a telephone-based care management intervention 
or to usual care. The intervention involved non-mental 
health professionals who provided patients with psycho-
education, assessed preferences for guideline-based care, 
monitored treatment responses, and informed physicians of 
their patients’ care preferences and progress. The usual care 
patients were informed of their anxiety condition both orally 
and in a written letter and they were given a disorder-speciﬁ  c 
brochure on their anxiety diagnosis, but neither the patients 
nor their physicians were provided with any additional 
patient-speciﬁ  c treatment advice. At 12-month follow-up, 
intervention patients reported reduced anxiety and depressive 
symptoms, improved mental health-related quality of life, 
larger improvements relative to baseline in hours worked 
per week, and fewer work days absent in the past month than 
usual care patients.
In a randomized, controlled study by Roy-Byrne et al 
(2005), 232 patients were randomized to receive either treat-
ment as usual or an intervention consisting of a combination 
of up to 6 sessions (across 12 weeks) of CBT modiﬁ  ed for 
the primary care setting, with up to 6 follow-up telephone 
contacts during the next 9 months, and algorithm-based 
pharmacotherapy provided by the primary care physician 
with guidance from a psychiatrist. The combined cognitive 
behavioral and pharmacotherapeutic intervention resulted in 
sustained and gradually increasing improvement relative to 
treatment as usual. The improvement was associated with a 
moderate increase in ambulatory costs (Katon et al 2006). 
According to the authors, the additional cost per additional 
anxiety-free day (AFD) and per quality adjusted life year 
(QALY) was well within the range of other commonly 
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accepted medical interventions such as statin use and 
treatment of hypertension.
Education, self-management,
and Internet-based interventions
Although PD with or without agoraphobia is often 
highly amenable to currently available treatments, either 
pharmacotherapy or CBT, or a combination of both, a con-
siderable proportion of sufferers do not beneﬁ  t from those 
treatments, either because they cannot ﬁ  nd a specialist to 
provide them, or because they do not know that such treat-
ments exist. As such, there is a need to bring these treatments 
to the attention of sufferers and to show them how they can 
best beneﬁ  t from them, without or with only limited help by 
a professional. This is where education, self- management, 
and Internet-based interventions come in.
Self-management interventions are a set of strategies used 
by people to manage the symptoms, treatment, and conse-
quences of disorders. Examples of self-help interventions 
include bibliotherapy, psychoeducation, computer-derived 
programs, Internet counseling, and peer group interven-
tions. They can be implemented when professional help is 
either unavailable, or when it is too costly, unwarranted, or 
not accepted by the patient. Self-help interventions still can 
involve professionals, but they usually include only limited 
direct contact with a professional. They rely heavily on the 
individual to practice self-management techniques. Patients 
who are intellectually and emotionally capable of under-
standing the nature of their disorder, as well as the types of 
treatment options available, and who are willing to invest 
considerable effort and time in the treatment of their disorder, 
may greatly proﬁ  t from such interventions and techniques.
The efﬁ  cacy of self-management interventions has been 
investigated in only a limited number of studies, and the 
methodology in many of those studies is far from perfect. 
There is, however, sufﬁ  cient evidence already to support fur-
ther investigations on self-management interventions for the 
treatment of PD with or without agoraphobia (Pull 2005).
Calbring et al (2007) have recently published the results 
of a study that provide evidence to support the use of treat-
ment distributed via the Internet with the addition of short 
weekly telephone calls to treat PD. The authors evaluated 
a 10-week Internet-based bibliotherapy self-help program 
with short weekly telephone calls for people suffering from 
PD with or without agoraphobia. Sixty participants were 
randomly assigned to either a wait-listed control group or a 
multimodal treatment package based on CBT plus minimal 
therapist contact via email. A 10-minute telephone call 
was made each week to support each participant. Total 
mean time spent on each participant during the 10 weeks 
was 3.9 hours. The participants were required to send in 
homework assignments before receiving the next treatment 
module. Analyses were conducted on an intention-to-treat 
basis, which included all randomly assigned participants. 
From pre-treatment to post-treatment, all treated participants 
improved signiﬁ  cantly on all measured dimensions (bodily 
interpretations, maladaptive cognitions, avoidance, general 
anxiety and depression levels, and quality of life). Treat-
ment gains on self-report measures were maintained at the 
9 month follow-up. A blind telephone interview after the 
end of treatment revealed that 77% of the treated patients 
no longer fulﬁ  lled the criteria for PD, whereas all of the 
waitlisted subjects still suffered from it.
Conclusion
Different pharmacological treatments as well as CBT are 
effective in the acute as well as in the long term treatment 
of PD with or without agoraphobia. First-line acute 
pharmacological treatments include different SSRIs such as 
paroxetine, ﬂ  uoxetine, ﬂ  uvoxamine, sertraline, citalopram, 
and escitalpram as well as the SNRI venlafaxine.
Other medications with proven efﬁ  cacy in PD include tri-
cyclic antidepressants, MAO inhibitors, and benzodiazepines. 
While several tricyclic antidepressants are effective treat-
ments for PD with or without agoraphobia, their use is limited 
by their side effects. While irreversible MAO inhibitors are 
effective treatments for PD with or without agoraphobia, 
their use is limited by their side effects and by their interac-
tions with other drugs and food components. Selective and 
RIMAs exempliﬁ  ed by moclobemide and brofaromine, do not 
require dietary restrictions, have fewer drug interactions than 
irreversible MAO inhibitors, and are better tolerated. High-
potency benzodiazepines such as lorazepam, alprazolam, and 
clonazepam are effective in treating PD and panic attacks with 
or without agoraphobia, alone or as add-on therapy to SSRIs. 
Although, as a class, benzodiazepines act rapidly and are well 
tolerated, their use presents clinical issues such as rebound 
anxiety, memory impairment, discontinuation syndrome, and 
a potential for abuse and dependence.
In long-term treatments with several medications, efﬁ  cacy 
was maintained or further increased in the long run, indicat-
ing the importance of long-term pharmacological treatment. 
Discontinuation of medication may result in relapse in a 
substantial proportion of patients.
CBT is a highly effective treatment for PD with or with-
out agoraphobia that compares favorably with any of the Neuropsychiatric Disease and Treatment 2008:4(4) 794
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pharmacological treatments in the acute phase of the treatment 
and may in fact be more effective in the long run.
Combining pharmacotherapy and CBT may be associated 
with greater overall efﬁ  cacy in the acute phase of the treat-
ment than either treatment alone. In the long-term treatment 
of PD with or without agoraphobia, combination treatments 
may be more effective than pharmacotherapy alone, but not 
more effective than CBT alone.
New strategies for combining pharmacotherapy and CBT, 
such as the sequential administration of pharmacotherapy 
and CBT, the combination of virtual reality exposure therapy 
and CBT, or the use of cognitive enhancers in combination 
with CBT have yielded promising results and should be 
investigated more fully in the years to come.
Finally, collaborative care strategies tailored for use in 
primary care as well as self-management interventions are 
more effective than usual care and should be further devel-
oped and reﬁ  ned.
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